The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Janus Kinase (JAK) Inhibitors Market Research Report 2025
Synopsis
JAK inhibitors are increasingly being used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis because of its proven efficacy in the treatment of various chronic diseases.
The global Janus Kinase (JAK) Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The high unmet need for the treatment of graft-versus-host disease (GVHD) has also encouraged market vendors to develop novel drugs for GVHD. The lack of approved therapies for the treatment of rare cancer indications will also boost the demand for JAK inhibitors.
This report aims to provide a comprehensive presentation of the global market for Janus Kinase (JAK) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Janus Kinase (JAK) Inhibitors.
Report Scope
The Janus Kinase (JAK) Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Janus Kinase (JAK) Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Janus Kinase (JAK) Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma, Inc.
Eli Lilly and Co.
Incyte Corp.
Novartis AG
Pfizer Inc.
Segment by Type
Ruxolitinib
Tofacitinib
Oclacitinib
Baricitinib
Peficitinib
Segment by Application
Autoimmune Disorders
Oncology
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Janus Kinase (JAK) Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
JAK inhibitors are increasingly being used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis because of its proven efficacy in the treatment of various chronic diseases.
The global Janus Kinase (JAK) Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The high unmet need for the treatment of graft-versus-host disease (GVHD) has also encouraged market vendors to develop novel drugs for GVHD. The lack of approved therapies for the treatment of rare cancer indications will also boost the demand for JAK inhibitors.
This report aims to provide a comprehensive presentation of the global market for Janus Kinase (JAK) Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Janus Kinase (JAK) Inhibitors.
Report Scope
The Janus Kinase (JAK) Inhibitors market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Janus Kinase (JAK) Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Janus Kinase (JAK) Inhibitors companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Astellas Pharma, Inc.
Eli Lilly and Co.
Incyte Corp.
Novartis AG
Pfizer Inc.
Segment by Type
Ruxolitinib
Tofacitinib
Oclacitinib
Baricitinib
Peficitinib
Segment by Application
Autoimmune Disorders
Oncology
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Janus Kinase (JAK) Inhibitors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Janus Kinase (JAK) Inhibitors Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Ruxolitinib
1.2.3 Tofacitinib
1.2.4 Oclacitinib
1.2.5 Baricitinib
1.2.6 Peficitinib
1.3 Market by Application
1.3.1 Global Janus Kinase (JAK) Inhibitors Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Autoimmune Disorders
1.3.3 Oncology
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Janus Kinase (JAK) Inhibitors Market Perspective (2019-2030)
2.2 Janus Kinase (JAK) Inhibitors Growth Trends by Region
2.2.1 Global Janus Kinase (JAK) Inhibitors Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Janus Kinase (JAK) Inhibitors Historic Market Size by Region (2019-2024)
2.2.3 Janus Kinase (JAK) Inhibitors Forecasted Market Size by Region (2025-2030)
2.3 Janus Kinase (JAK) Inhibitors Market Dynamics
2.3.1 Janus Kinase (JAK) Inhibitors Industry Trends
2.3.2 Janus Kinase (JAK) Inhibitors Market Drivers
2.3.3 Janus Kinase (JAK) Inhibitors Market Challenges
2.3.4 Janus Kinase (JAK) Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Janus Kinase (JAK) Inhibitors Players by Revenue
3.1.1 Global Top Janus Kinase (JAK) Inhibitors Players by Revenue (2019-2024)
3.1.2 Global Janus Kinase (JAK) Inhibitors Revenue Market Share by Players (2019-2024)
3.2 Global Janus Kinase (JAK) Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Janus Kinase (JAK) Inhibitors Revenue
3.4 Global Janus Kinase (JAK) Inhibitors Market Concentration Ratio
3.4.1 Global Janus Kinase (JAK) Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Janus Kinase (JAK) Inhibitors Revenue in 2023
3.5 Janus Kinase (JAK) Inhibitors Key Players Head office and Area Served
3.6 Key Players Janus Kinase (JAK) Inhibitors Product Solution and Service
3.7 Date of Enter into Janus Kinase (JAK) Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Janus Kinase (JAK) Inhibitors Breakdown Data by Type
4.1 Global Janus Kinase (JAK) Inhibitors Historic Market Size by Type (2019-2024)
4.2 Global Janus Kinase (JAK) Inhibitors Forecasted Market Size by Type (2025-2030)
5 Janus Kinase (JAK) Inhibitors Breakdown Data by Application
5.1 Global Janus Kinase (JAK) Inhibitors Historic Market Size by Application (2019-2024)
5.2 Global Janus Kinase (JAK) Inhibitors Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Janus Kinase (JAK) Inhibitors Market Size (2019-2030)
6.2 North America Janus Kinase (JAK) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Janus Kinase (JAK) Inhibitors Market Size by Country (2019-2024)
6.4 North America Janus Kinase (JAK) Inhibitors Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Janus Kinase (JAK) Inhibitors Market Size (2019-2030)
7.2 Europe Janus Kinase (JAK) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Janus Kinase (JAK) Inhibitors Market Size by Country (2019-2024)
7.4 Europe Janus Kinase (JAK) Inhibitors Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Janus Kinase (JAK) Inhibitors Market Size (2019-2030)
8.2 Asia-Pacific Janus Kinase (JAK) Inhibitors Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Janus Kinase (JAK) Inhibitors Market Size by Region (2019-2024)
8.4 Asia-Pacific Janus Kinase (JAK) Inhibitors Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Janus Kinase (JAK) Inhibitors Market Size (2019-2030)
9.2 Latin America Janus Kinase (JAK) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Janus Kinase (JAK) Inhibitors Market Size by Country (2019-2024)
9.4 Latin America Janus Kinase (JAK) Inhibitors Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Janus Kinase (JAK) Inhibitors Market Size (2019-2030)
10.2 Middle East & Africa Janus Kinase (JAK) Inhibitors Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Janus Kinase (JAK) Inhibitors Market Size by Country (2019-2024)
10.4 Middle East & Africa Janus Kinase (JAK) Inhibitors Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Pharma, Inc.
11.1.1 Astellas Pharma, Inc. Company Detail
11.1.2 Astellas Pharma, Inc. Business Overview
11.1.3 Astellas Pharma, Inc. Janus Kinase (JAK) Inhibitors Introduction
11.1.4 Astellas Pharma, Inc. Revenue in Janus Kinase (JAK) Inhibitors Business (2019-2024)
11.1.5 Astellas Pharma, Inc. Recent Development
11.2 Eli Lilly and Co.
11.2.1 Eli Lilly and Co. Company Detail
11.2.2 Eli Lilly and Co. Business Overview
11.2.3 Eli Lilly and Co. Janus Kinase (JAK) Inhibitors Introduction
11.2.4 Eli Lilly and Co. Revenue in Janus Kinase (JAK) Inhibitors Business (2019-2024)
11.2.5 Eli Lilly and Co. Recent Development
11.3 Incyte Corp.
11.3.1 Incyte Corp. Company Detail
11.3.2 Incyte Corp. Business Overview
11.3.3 Incyte Corp. Janus Kinase (JAK) Inhibitors Introduction
11.3.4 Incyte Corp. Revenue in Janus Kinase (JAK) Inhibitors Business (2019-2024)
11.3.5 Incyte Corp. Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Detail
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Janus Kinase (JAK) Inhibitors Introduction
11.4.4 Novartis AG Revenue in Janus Kinase (JAK) Inhibitors Business (2019-2024)
11.4.5 Novartis AG Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Detail
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Janus Kinase (JAK) Inhibitors Introduction
11.5.4 Pfizer Inc. Revenue in Janus Kinase (JAK) Inhibitors Business (2019-2024)
11.5.5 Pfizer Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
